ClinicalTrials.gg
CompletedNCT03238027Updated May 17, 2024

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

A Phase 1 interventional study of Axatilimab and Durvalumab in Solid Tumor, Metastatic Tumor and Locally Advanced Malignant Neoplasm, sponsored by Syndax Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Syndax Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
891st of 1,863
45 · median 43
Started
2017
with 79 others
Phase 1
709 of 2,054
128 open now
Registered
1,186th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 891st largest by enrollment of the 1,863 interventional ones that give a count, is one of 80 that started in 2017, is one of 709 in phase 1, and was the 1,186th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.

Read the detailed description

This is an open label, multi-center Phase 1 study consisting of Phase 1a and Phase 1b. The study will evaluate axatilimab monotherapy (in Phase 1a) and axatilimab combined with durvalumab (in Phase 1b) in patients with advanced solid tumors which must have progressed following prior treatment and have no standard therapy alternatives left (i.e., patients must not be candidates for regimens known to provide clinical benefit). The primary objective will be to determine the MTD and/or RP2D of axatilimab as monotherapy (Phase 1a) and in combination with durvalumab (Phase 1b) as evaluated by the incidence of AEs that are defined as DLTs. In both study phases, a standard "3+3" dose escalation schema will be used to determine an MTD with 3-6 evaluable patients enrolled per dose level. The RP2D will be determined based on data from the dose escalation patients as reviewed by the Safety Review Committee (SRC; comprised of investigators and the Sponsor).

03

Conditions studied

  • Solid Tumor
  • Metastatic Tumor
  • Locally Advanced Malignant Neoplasm
  • Unresectable Malignant Neoplasm

Browse trials for

Keywords

  • SNDX-6352
  • CSF-1R inhibitor
  • Colony Stimulating factor 1 receptor inhibitor
  • Solid Tumor
  • Recurrent locally advanced tumor
  • unresectable solid tumor
  • Metastatic tumor
  • durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA:

Inclusion Criteria for Phase 1a and Phase 1b

Patients meeting all of the following criteria are considered eligible to participate in the study:

  1. Signed written form (ICF).
  2. Male or female patients aged ≥18 years.
  3. Patients with histopathologically confirmed unresectable, recurrent, locally advanced, or solid tumors, with evaluable disease and must have progressed following prior treatment and have no standard therapy alternatives left (i.e., patients must not be candidates for regimens known to provide clinical benefit).
  4. performance status (ECOG PS) of 0 or 1 at the study enrollment.
  5. Has adequate organ and bone marrow function within 21 days before enrollment as defined below:

    a. Hematological laboratory values: i. (ANC) ≥1.5 × 10\^9/L ii. ≥100 × 10\^9/L iii. ≥9 g/dL b. Renal laboratory values: i. Creatinine ≤1.5 times the (ULN) OR ii. Measured or calculated (per institutional standard) (CrCl) ≥60 mL/min according to the Cockcroft-Gault formula or measured 24-hour creatinine clearance (or local institutional standard measure) for patient with creatinine level > 1.5 times institutional ULN.

    iii. may be used instead of creatinine or CrCl. c. Hepatic laboratory values: i. Total ≤1.5 times ULN or ii. Direct bilirubin ≤ULN for patients with total bilirubin >1.5 times ULN iii. and ALT ≤2.5 times ULN d. Creatine kinase ≤ ULN

  6. Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ≤1 (except alopecia) per v5.0 If a patient underwent major surgery or radiation therapy of >30 Gray, the patient must have recovered from the toxicity and/or complications from the intervention.

    Note: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.

  7. Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  8. Female patients of who are not abstinent and intend to be sexually active with a nonsterilized male partner must use at least 1 highly effective method of (Table 11) from the time of screening throughout the total duration of the study drug treatment and 90 days after the last dose of study drug. Non-sterilized male partners of a female patient of childbearing potential must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period.
  9. Non-sterilized male patients who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom plus spermicide from the time of screening throughout the total duration of the study drug treatment and 90 days after the last dose of study drug. However, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients should refrain from sperm donation throughout this period.
  10. Must have a of at least 12 weeks.

Additional Inclusion Criteria for Phase 1b 11. Body weight > 30 kg 12. No prior exposure to immune-mediated therapy including, but not limited to, other anti , anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines.

EXCLUSION CRITERIA:

Exclusion Criteria for Phase 1a and Phase 1b

Patients meeting any of the following criteria are not eligible for study participation:

  1. Diagnosis of immunodeficiency or receiving systemic therapy or any other form of therapy within 14 days prior to the first dose of study drug.

    a. Exceptions: 1) The use of physiologic doses of corticosteroids (i.e., ≤10 mg per day of equivalent prednisone) is allowed; 2) Steroids with no or minimal systemic effect (topical, inhalation) are allowed; 3) Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment; (4) Steroids as premedication for reactions (e.g., CT scan premedication).

  2. Previously treated with a CSF-1, CSF-1R, and/or IL-34-blocking agents
  3. Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  4. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the patient's best interest to participate, in the opinion of the treating Investigator, including, but not limited to:

    1. Active or prior documented or inflammatory disorders (see Appendix 3 for complete list).
    2. History of active primary immunodeficiency
    3. Known active or latent tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice).
    4. Myocardial infarction or arterial thromboembolic events within 6 months prior to enrollment or severe or unstable angina, (NYHA) (see Appendix 2) Class III or IV disease, or a > 470 msec. History of QTc prolongation, ventricular fibrillation, ventricular tachycardia or Torsades de Pointes (TdP).
    5. Symptomatic congestive heart failure, cardiac arrhythmia, uncontrolled hypertension or diabetes mellitus.
    6. Active infection requiring systemic therapy.
    7. Interstitial lung disease
    8. Serious chronic gastrointestinal conditions associated with diarrhea
    9. Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis identified either on the baseline brain imaging (please see Appendix A ()) for details on the imaging modality) obtained during the screening period or identified prior to signing the ICF. Patients whose have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10 mg/day of prednisone or its equivalent for at least 14 days prior to the start of treatment. Brain metastases will not be recorded as RECIST Target Lesions at baseline.
  5. Received a within 30 days of the first dose of study drug.

    Note: Patients, if enrolled, should not receive live vaccine whilst receiving study drug and up to 30 days after the last dose of study drug.

  6. Administration of colony stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage-colony stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to the first dose of study drug treatment.
  7. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  8. Received chemotherapy, anti-cancer mAb, targeted small molecule or other systemic anti-cancer therapy within 4 weeks of the first dose of study drug. However, patients receiving conventional and small molecule targeted therapies that are not expected to have delayed toxicities may enter the study 5 half-lives or 28 days after the last dose of the compound, whichever is shorter.
  9. Currently receiving treatment with any other agent listed on the prohibited medication list.
  10. Known history of (HIV) (HIV 1/2 antibodies).
  11. Known active (e.g., hepatitis B surface antigen-reactive) or (e.g., hepatitis C virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  12. Known alcohol or drug abuse.
  13. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  14. Legal incapacity or limited legal capacity.
  15. Evidence of muscle disorders or muscle injury that are known to cause serum creatine kinase (CK) elevation
  16. Current pneumonitis or has a history of (non-infectious) pneumonitis that required steroids
  17. Known allergy or hypersensitivity to any of the study drugs or any of the study drug .
  18. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study drug. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  19. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks or palliative radiation therapy within 2 weeks of the first dose of study drug
  20. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective birth control from screening to 90 days after the last dose of study drug

    Additional Exclusion Criteria for Phase 1b

  21. History of allogenic organ transplantation.
  22. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Ph1a D1: 1 mg/kg Axatilimab

    Three (3) patients receive starting dose of 1 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab

  • Experimental
    Ph1a D2: 3 mg/kg Axatilimab

    Three (3) patients receive next higher dose of 3 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab

  • Experimental
    Ph1a D3: 6 mg/kg Axatilimab

    Three (3) patients receive next higher dose of 6 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab

  • Experimental
    Ph1a D4: 10 mg/kg Axatilimab

    Three (3) patients receive next higher dose of 10 mg/kg of axatilimab and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab

  • Experimental
    Ph1b D1: 1 mg/kg Axatilimab+1500 mg durvalumab

    Three (3) patients receive starting dose of 1 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg axatilimab dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.

    Drug: Axatilimab · Drug: Durvalumab

  • Experimental
    Ph1b D2: 3 mg/kg Axatilimab+1500 mg durvalumab

    Three (3) patients receive next higher dose of 3 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab · Drug: Durvalumab

  • Experimental
    Ph1b D3: 6 mg/kg Axatilimab+1500 mg durvalumab

    Three (3) patients receive next higher dose of 6 mg/kg of axatilimab every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.

    Drug: Axatilimab · Drug: Durvalumab

Interventions

  • Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

    Also known as: SNDX-6352

  • Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Phase 1a: Determination of any Dose limiting toxicities (DLT)s of Axatilimab

    All patients treated with axatilimab across all treatment arms (dosing levels) will have safety assessed in order to determine any dose-limiting toxicities (DLT)s.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

  2. Phase 1a: Determination of Maximum tolerable dose (MTD) of Axatilimab

    All patients treated with axatilimab across all treatment arms (dosing levels) will have safety assessed in order to determine the MTD.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

  3. Phase 1a: Determination of Recommended Phase 2 dose (RP2D) of Axatilimab

    All patients treated with axatilimab across all treatment arms (dosing levels) will have safety assessed in order to determine the RP2D.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

  4. Phase 1b: Determination of any Dose limiting toxicities (DLT)s of Axatilimab when given in combination with a fixed dose of durvalumab

    All patients treated with axatilimab in combination with a fixed dose of durvalumab across all treatment arms (dosing levels) will have safety assessed in order to determine any dose-limiting toxicities (DLT)s.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

  5. Phase 1b: Determination of Maximum tolerable dose (MTD) of Axatilimab when given in combination with a fixed dose of durvalumab

    All patients treated with axatilimab in combination with a fixed dose of durvalumab across all treatment arms (dosing levels) will have safety assessed in order to determine the MTD.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

  6. Phase 1b: Determination of Recommended Phase 2 dose (RP2D) of Axatilimab when given in combination with a fixed dose of durvalumab

    All patients treated with axatilimab in combination with a fixed dose of durvalumab across all treatment arms (dosing levels) will have safety assessed in order to determine the RP2D.

    Time frame: Approximately 9 months (from first dose to 90-day follow-up post-last dose)

Secondary outcomes

  1. Phase 1a: PK endpoint of Cmax (maximum observed concentration) for Axatilimab as dose levels increase across different treatment groups.

    Cmax for SDNX-6352 for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  2. Phase 1a: PK endpoint of AUC (area under the curve) for Axatilimab as dose levels increase across different treatment groups.

    AUC for SDNX-6352 for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  3. Phase 1a: PK endpoint of Tmax (time to reach maximum observed concentration) for Axatilimab as dose levels increase across different treatment groups.

    Tmax for SDNX-6352 for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  4. Phase 1a: PK endpoint of T1/2 (apparent terminal elimination half life)) for Axatilimab as dose levels increase across different treatment groups.

    T1/2 for SDNX-6352 for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  5. Phase 1a: Evaluation of preliminary anti-tumor activity of Axatilimab on solid tumors

    To determine if the size and number of target lesions changes in response to treatment with axatilimab by analyzing CT-Scans/MRIs per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and irRECIST.

    Time frame: Approximately 9 months (from baseline scan to 90-day follow-up post-last dose)

  6. Phase 1a: Effect of Axatilimab on CSF-1 and IL-34

    To assess change from Baseline in plasma CSF-1 and IL-34 following IV administration

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  7. Phase 1a: Evaluate the immunogenicity of Axatilimab

    To assess the immunogenicity of axatilimab as measured by presence of anti-drug antibodies (ADA)

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  8. Phase 1b: PK endpoint of Cmax (maximum observed concentration) for Axatilimab when given in combination with a fixed dose of durvalumab as dose levels increase across different treatment groups.

    Cmax for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  9. Phase 1b: PK endpoint of AUC (area under the curve) for Axatilimab when given in combination with a fixed dose of durvalumab as dose levels increase across different treatment groups.

    AUC for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  10. Phase 1b: PK endpoint of Tmax (time to reach maximum observed concentration) for Axatilimab when given in combination with a fixed dose of durvalumab as dose levels increase across different treatment groups.

    Tmax for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  11. Phase 1b: PK endpoint of T1/2 (apparent terminal elimination half-life)) for Axatilimab when given in combination with a fixed dose of durvalumab as dose levels increase across different treatment groups.

    T1/2 for axatilimab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  12. Phase 1b: PK endpoint of Cmax (maximum observed concentration) for durvalumab when given in combination with Axatilimab as dose levels increase across different treatment groups.

    Cmax for durvalumab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  13. Phase 1b: PK endpoint of AUC (area under the curve) for durvalumab when given in combination with Axatilimab as dose levels increase across different treatment groups.

    AUC for durvalumab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  14. Phase 1b: PK endpoint of Tmax (time to reach maximum observed concentration) for durvalumab when given in combination with Axatilimab as dose levels increase across different treatment groups.

    Tmax for durvalumab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  15. Phase 1b: PK endpoint of T1/2 (apparent terminal elimination half-life) for durvalumab when given in combination with Axatilimab as dose levels increase across different treatment groups.

    T1/2 for durvalumab will be computed.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  16. Phase 1b: Evaluation of preliminary anti-tumor activity of Axatilimab when given in combination with a fixed dose of durvalumab on solid tumors.

    To determine if the size and number of target lesions changes in response to treatment with axatilimab by analyzing CT-Scans/MRIs per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and irRECIST.

    Time frame: Approximately 9 months (from baseline scan to 90-day follow-up post-last dose)

  17. Phase 1b: Effect of Axatilimab on CSF-1 and IL-34

    To assess change from Baseline in plasma CSF-1 and IL-34 following IV administration

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  18. Phase 1b: Evaluation of the immunogenicity of Axatilimab

    To assess the immunogenicity of axatilimab as measured by presence of anti-drug antibodies (ADA)

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  19. Phase 1b: Evaluation of the immunogenicity of durvalumab

    To assess the immunogenicity of durvalumab as measured by presence of anti-drug antibodies (ADA)

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

Other outcomes

  1. Phase 1a: Effect of Axatilimab on CSF-1 receptor occupancy

    To evaluate the change from Baseline in CSF-1 receptor occupancy (RO)

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  2. Phase 1a: Exploration of relationship between candidate biomarker results and anti-tumor activity of Axatilimab

    To investigate the relationship between candidate biomarkers (e.g., CSF-1, IL-34) and anti-tumor activity of axatilimab

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  3. Phase 1a: Exploration of relationship between additional biomarkers and anti-tumor activity of Axatilimab

    To investigate the relationship between other biomarkers (e.g., tumor infiltrating lymphocytes, PD-L1, PD-1, PD-L2, circulating classical and non-classical CD-16 monocytes in blood) and anti-tumor activity of axatilimab

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  4. Phase 1a: Characterization of relationship in change from baseline in CSF-1, IL-34, etc. with Axatilimab administered intravenously.

    To characterize the relationship in change from baseline in plasma colony stimulating factor-1 \[CSF-1\] interleukin-34 \[IL-34\]), and IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, CXCL8/IL-8, IL-10, IL-12 (p70), IL-13, TNF-alpha, CD204/206 and sCD163 with systemic PK of axatilimab administered intravenously.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  5. Phase 1b: Characterization of the PD profile of Axatilimab and durvalumab when given in combination.

    To characterize the pharmacodynamic (PD) profile of axatilimab and durvalumab when given in combination in patients with advanced solid tumors.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  6. Phase 1b:Effect of Axatilimab when given in combination with a fixed dose of durvalumab on CSF-1 receptor occupancy.

    To evaluate the change from Baseline in CSF-1 receptor occupancy (RO).

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  7. Phase 1b: Exploration of relationship between candidate biomarker results and anti-tumor activity of Axatilimab when given in combination with a fixed dose of durvalumab.

    To investigate the relationship between candidate biomarkers (e.g., CSF-1, IL-34) and anti-tumor activity of axatilimab when given in combination with a fixed dose of durvalumab.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  8. Phase 1b: Exploration of relationship between additional biomarkers and anti-tumor activity of Axatilimab when given in combination with a fixed dose of durvalumab.

    To investigate the relationship between other biomarkers (e.g., tumor infiltrating lymphocytes, PD-L1, PD-1, PD-L2, circulating classical and non-classical CD-16 monocytes in blood) and anti-tumor activity of axatilimab when given in combination with a fixed dose of durvalumab.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

  9. Phase 1b: Characterization of relationship in change from baseline in CSF-1, IL-34, etc. with Axatilimab administered intravenously when given in combination with a fixed dose of durvalumab.

    To characterize the relationship in change from baseline in plasma colony stimulating factor-1 \[CSF-1\] interleukin-34 \[IL-34\]), and IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, CXCL8/IL-8, IL-10, IL-12 (p70), IL-13, TNF-alpha, CD204/206 and sCD163 with systemic PK of axatilimab administered intravenously when given in combination with a fixed dose of durvalumab.

    Time frame: Approximately 6 months (from first dose to End of Treatment visit)

07

Study locations

5 sites
  • Honor Health
    Scottsdale, Arizona 85258, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2020, 38 months.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 38 months is below that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Aug 3, 2017
StartActual
Sep 1, 2017
Primary completionActual
Nov 20, 2020
CompletionActual
Nov 20, 2020
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03238027
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Sep 1, 2017
Primary completion
Nov 20, 2020
Completion
Nov 20, 2020
Last update
May 17, 2024

Study contacts

Kate Madigan, MD
study director · Syndax Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion